From the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Farooq is currently located at Great Lakes Pathologists S.C. in Milwaukee, Wisconsin.
Arch Pathol Lab Med. 2024 Aug 1;148(8):898-904. doi: 10.5858/arpa.2023-0178-OA.
CONTEXT.—: Nuclear protein in testis (NUT) carcinoma is an aggressive carcinoma defined by NUTM1 gene rearrangement. Diagnostic challenges include morphologic overlap with poorly differentiated squamous cell carcinoma, small cell carcinoma, thoracic SMARCA4-deficient undifferentiated tumor, and other small round blue cell tumors.
OBJECTIVE.—: To comprehensively study the immunohistochemistry (IHC) features of a large cohort of NUT carcinomas.
DESIGN.—: Fifty-seven NUT carcinoma cases were identified from 2012-2022, including 38 thoracic/mediastinal, 13 head and neck/sinonasal, and 6 from other sites. Pathology reports and available slides were reviewed. Comprehensive IHC studies were performed on available cases.
RESULTS.—: Keratin stains showed variable positivity and were entirely negative in 15% (8 of 55) of cases. p40 was only positive in 65% (24 of 37) of cases, implying inferior sensitivity when compared to p63 (87% sensitivity, 20 of 23 cases) and other squamous cell markers. Neuroendocrine markers were focally/weakly positive in few cases; however, INSM1 was positive in 54% (7 of 13) of cases, indicating a possible diagnostic pitfall. TTF-1 was mostly negative with focal positivity in 26% (10 of 38) of cases. Occasional CD34 (15%, 3 of 20 cases) and CD99 (21%, 3 of 14 cases) positivity could also cause potential diagnostic confusion. S100, desmin, CD45, and SALL4 were rarely positive. BRG1 and INI1 were retained in all cases. Ki-67 proliferative index was high (median, 60%). PD-L1 was negative in all tested cases.
CONCLUSIONS.—: This comprehensive IHC study demonstrates the immunohistochemical spectrum of NUT carcinoma. The findings can help narrow the differential diagnosis and recognize potential pitfalls.
睾丸核蛋白(NUT)癌是一种侵袭性癌,由 NUTM1 基因重排定义。诊断挑战包括与低分化鳞状细胞癌、小细胞癌、胸 SMARCA4 缺陷未分化肿瘤和其他小圆蓝细胞肿瘤的形态学重叠。
全面研究大系列 NUT 癌的免疫组织化学(IHC)特征。
从 2012 年至 2022 年共确定了 57 例 NUT 癌病例,包括 38 例胸/纵隔、13 例头颈部/鼻旁窦和 6 例其他部位。回顾了病理学报告和现有幻灯片。对现有病例进行了全面的 IHC 研究。
角蛋白染色显示变异性阳性,在 15%(8/55)的病例中完全阴性。p40 仅在 65%(24/37)的病例中阳性,与 p63(87%敏感性,20/23 例)和其他鳞状细胞标志物相比敏感性较低。神经内分泌标志物在少数病例中呈局灶性/弱阳性;然而,INSM1 在 54%(13/13)的病例中阳性,表明存在潜在的诊断陷阱。TTF-1 大多为阴性,26%(38/14)的病例为局灶性阳性。偶尔 CD34(15%,20/137 例)和 CD99(21%,14/14 例)阳性也可能导致潜在的诊断混淆。S100、结蛋白、CD45 和 SALL4 很少阳性。BRG1 和 INI1 在所有病例中均保留。Ki-67 增殖指数高(中位数,60%)。所有测试病例的 PD-L1 均为阴性。
这项全面的 IHC 研究展示了 NUT 癌的免疫组织化学谱。这些发现可以帮助缩小鉴别诊断范围,并识别潜在的陷阱。